Publications by authors named "L E Terranova"
Article Synopsis
- - The introduction of ETI therapy has improved life expectancy for adults with cystic fibrosis, but it raises concerns about long-term health issues, particularly cardiovascular risks due to existing factors linked to CF.
- - A study involving 58 adults with CF assessed changes in cardiac and metabolic biomarkers after 6 months on ETI therapy, revealing increased cholesterol and triglycerides levels while inflammatory markers decreased.
- - The findings indicate a disruption in hormone regulation related to obesity and cardiovascular risk, suggesting that while ETI improves some aspects of health, it negatively affects lipid profiles in patients, leading to potential metabolic issues.
Article Synopsis
- A cluster of four patients with CRAB, who had never been treated with FDC, showed non-susceptibility to FDC due to a specific mutation in the PirA protein, which included a premature stop codon and amino acid deletion.
- Between March and July 2024, 33 CRAB cases were identified in a single hospital ward, with genetic analysis revealing that four of these cases were closely related variants showing reduced FDC susceptibility.
- The study emphasizes the need for careful testing of FDC susceptibility in patients, as the identified clones suggest possible transmission of resistant strains even in those without prior treatment.
A-kinase anchoring proteins (AKAPs) are key orchestrators of cAMP signaling that act by recruiting protein kinase A (PKA) in proximity of its substrates and regulators to specific subcellular compartments. Modulation of AKAPs function offers the opportunity to achieve compartment-restricted modulation of the cAMP/PKA axis, paving the way to new targeted treatments. For instance, blocking the AKAP activity of phosphoinositide 3-kinase γ (PI3Kγ) improves lung function by inducing cAMP-mediated bronchorelaxation, ion transport, and antiinflammatory responses.
View Article and Find Full Text PDFBackground: Group A Streptococcus (GAS) causes multiple clinical manifestations, including invasive (iGAS) or even life-threatening (severe-iGAS) infections. After the drop in cases during COVID-19 pandemic, in 2022 a sharp increase of GAS was reported globally.
Methods: GAS strains collected in 09/2022-03/2023 in two university hospitals in Milan, Italy were retrospectively analyzed.
Objectives: To compare intensivist-diagnosed ventilator-associated pneumonia (iVAP) with four established definitions, assessing their agreement in detecting new episodes.
Methods: A multi-centric prospective study on pulmonary microbiota was carried out in patients requiring mechanical ventilation (MV). Data collected were used to compare hypothetical VAP onset according to iVAP with the study consensus criteria, the European Centre for Disease Control and Prevention definition, and two versions of the latter adjusted for leukocyte count and fever.